GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...

The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

For the quarter ended June 2025, GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million, up 1.2% over the same period last year. EPS came in at $0.09, compared to $0.08 in the year-ago ...

GoodRx (GDRX) delivered earnings and revenue surprises of -10.00% and -1.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?